1. Home
  2. ERAS vs TEN Comparison

ERAS vs TEN Comparison

Compare ERAS & TEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • TEN
  • Stock Information
  • Founded
  • ERAS 2018
  • TEN 1993
  • Country
  • ERAS United States
  • TEN Greece
  • Employees
  • ERAS N/A
  • TEN N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • TEN
  • Sector
  • ERAS Health Care
  • TEN
  • Exchange
  • ERAS Nasdaq
  • TEN NYSE
  • Market Cap
  • ERAS 432.6M
  • TEN 496.6M
  • IPO Year
  • ERAS 2021
  • TEN N/A
  • Fundamental
  • Price
  • ERAS $1.37
  • TEN $17.05
  • Analyst Decision
  • ERAS Strong Buy
  • TEN Buy
  • Analyst Count
  • ERAS 6
  • TEN 2
  • Target Price
  • ERAS $4.83
  • TEN $31.00
  • AVG Volume (30 Days)
  • ERAS 1.8M
  • TEN 285.4K
  • Earning Date
  • ERAS 03-20-2025
  • TEN 03-27-2025
  • Dividend Yield
  • ERAS N/A
  • TEN 8.79%
  • EPS Growth
  • ERAS N/A
  • TEN N/A
  • EPS
  • ERAS N/A
  • TEN 5.03
  • Revenue
  • ERAS N/A
  • TEN $804,061,000.00
  • Revenue This Year
  • ERAS N/A
  • TEN N/A
  • Revenue Next Year
  • ERAS N/A
  • TEN $9.03
  • P/E Ratio
  • ERAS N/A
  • TEN $3.42
  • Revenue Growth
  • ERAS N/A
  • TEN N/A
  • 52 Week Low
  • ERAS $1.23
  • TEN $15.05
  • 52 Week High
  • ERAS $3.45
  • TEN $31.48
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 39.36
  • TEN 53.17
  • Support Level
  • ERAS $1.40
  • TEN $15.94
  • Resistance Level
  • ERAS $1.61
  • TEN $17.50
  • Average True Range (ATR)
  • ERAS 0.11
  • TEN 0.72
  • MACD
  • ERAS 0.01
  • TEN 0.12
  • Stochastic Oscillator
  • ERAS 4.00
  • TEN 80.35

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About TEN TSAKOS ENERGY NAVIGATION

Tsakos Energy Navigation Ltd is a seaborne transportation service provider for crude oil and petroleum products. The company's carriers cater to national and international independent oil companies and refiners. It generates revenue through charter contracts with its clients, which include time, bareboat, and voyage charters, contracts of affreightment, and pool arrangements.

Share on Social Networks: